Hepatitis C virus NS5A inhibitors and drug resistance mutations

doi:10.3748/wjg.v20.i11.2902

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 11

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9944)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

994

WORD

386

HTML

6421

Figures (1-3)

178

Tables (1-2)

145

Sum=8124

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

954

Download

865

Sum=1819

Mar 21, 2014 (publication date) through Apr 24, 2024

Times Cited of This Article

Times Cited (105)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Mar 21, 2014; 20(11): 2902-2912
Published online Mar 21, 2014. doi: 10.3748/wjg.v20.i11.2902

Full Size Figure Download Figure

Figure 3 Algorithm of current hepatitis C virus treatment options. A: Hepatitis C virus (HCV) genotype 1 patients; B: HCV genotype 2 patients; C: Interferon (IFN)-free regimens. G1: Genotype 1; G2: Genotype 2; RBV: Ribavirin; NI: Nucleoside inhibitor; PI: Protease inhibitor.

Citation: Nakamoto S, Kanda T, Wu S, Shirasawa H, Yokosuka O. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J Gastroenterol 2014; 20(11): 2902-2912
URL: https://www.wjgnet.com/1007-9327/full/v20/i11/2902.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i11.2902